NMRA
Neumora Therapeutics, Inc. Common StockNASDAQHealthcare$2.00+6.00%ClosedMarket Cap: $334.2M
As of 2026-04-06
Valuation
P/E (TTM)
—
PEG
—
P/B
3.33
P/S
0.00
EV/EBITDA
-0.72
DCF Value
$1.10
FCF Yield
-58.3%
Div Yield
0.0%
Margins & Returns
Gross Margin
0.0%
Operating Margin
0.0%
Net Margin
0.0%
ROE
-146.4%
ROA
-124.0%
ROIC
-151.8%
Income Statement
| Period | Revenue | Gross Margin | Operating Income | Net Income | EPS | Dividend |
|---|---|---|---|---|---|---|
| Q4 2025 | $0.00 | NaN% | $-58.5M | $-59.5M | $-0.35 | — |
| FY 2025 | $0.00 | -Infinity% | $-241.2M | $-236.9M | $-1.45 | — |
| Q3 2025 | $0.00 | -Infinity% | $-57.7M | $-56.8M | $-0.35 | — |
| Q2 2025 | $0.00 | NaN% | $-54.0M | $-52.7M | $-0.33 | — |
| Q1 2025 | $0.00 | NaN% | $-70.9M | $-68.0M | $-0.42 | — |
| Q4 2024 | $0.00 | NaN% | $-62.9M | $-58.8M | $-0.37 | — |
| FY 2024 | $0.00 | NaN% | $-263.5M | $-243.8M | $-1.53 | — |
| Q3 2024 | $0.00 | NaN% | $-76.6M | $-72.5M | $-0.45 | — |
| Q2 2024 | $0.00 | NaN% | $-63.8M | $-58.7M | $-0.37 | — |
| Q1 2024 | $0.00 | NaN% | $-60.1M | $-53.7M | $-0.34 | — |
| Q4 2023 | $0.00 | -Infinity% | $-50.1M | $-108.7M | $-0.68 | — |
| FY 2023 | $0.00 | -Infinity% | $-188.2M | $-235.9M | $-1.49 | — |